Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 8/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553358 | 1.00 | MAOB (0.41) | MAOBACACBMAOASLC6A2SLC6A4 | |
| SCHEMBL2546225 | 0.90 | MAOB (0.39) | MAOBACACBMAOASLC6A2SLC6A4 | |
| SCHEMBL2546222 | 0.90 | MAOB (0.39) | MAOBACACBMAOASLC6A2SLC6A4 | |
| SCHEMBL2548605 | 0.86 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL2548606 | 0.86 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL2550836 | 0.84 | MAOB (0.38) | MAOBACACBMAOAACHEMTNR1A | |
| SCHEMBL2550833 | 0.84 | MAOB (0.38) | MAOBACACBMAOAACHEMTNR1A | |
| SCHEMBL14734872 | 0.84 | MAOB (0.41) | MAOBACACBMAOASLC6A2SLC6A4 | |
| SCHEMBL14734873 | 0.84 | CA12 (0.41) | MAOBMAOASLC6A2SLC6A4HTR3A | |
| SCHEMBL2552415 | 0.83 | MAOB (0.43) | MAOBACACBMAOAMTNR1AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563765-B1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-8703758-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-22 | — | — | US | disclosed |
| WO-2011136385-A1 | BICYCLIC COMPOUND DERIVATIVES AND THEIR USE AS ACC INHIBITORS. | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-03 | — | — | WO | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | MAOB 3507/4885ACACB 3/4885MAOA 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.